Vitalis Therapeutics Inc. — A plain-English guide to how a drug gets from a selected molecule to a pharmacy shelf, and where program management fits. Written for a reader who does not work in pharmaceutical development. Uses the VitaFlow (VTX-401) program throughout as the worked example.
1. The Shape of the Whole Thing
A drug takes roughly six to ten years to get from a selected molecule to a pharmacy shelf, and most attempts fail. Understanding why it takes that long, and where the failures happen, is the foundation everything else rests on.
The sequence is fixed and cannot be reordered:
| Stage | Question it answers | Typical duration |
|---|---|---|
| Discovery | Is there a molecule worth testing? | 2–5 years |
| Nonclinical | Is it safe enough to give a human? | 1–2 years |
| IND | Will the agency let us start? | 30 days |
| Phase 1 | Is it safe in people, and what does the body do to it? | 6–12 months |
| Phase 2 | Does it work, and at what dose? | 1–2 years |
| Phase 3 | Does it work at scale, safely, against a control? | 2–4 years |
| NDA review | Will the agency approve the label we asked for? | 10–12 months |
| Launch | Can we supply it and will anyone pay for it? | ongoing |
Every structural feature of pharmaceutical program management follows from that number. Staged funding exists because most programs should stop. Gates exist because the information arrives in discrete lumps. Governance is designed around termination being the normal outcome, not the failure case.
2. Before a Human Is Dosed
Nonclinical — the safety package
Before any person receives the drug, the sponsor must have evidence that a reasonable starting dose is unlikely to hurt them. That evidence comes from animal studies conducted under Good Laboratory Practice (GLP): toxicology at escalating doses, safety pharmacology on the cardiovascular, respiratory and nervous systems, and pharmacokinetics establishing how the body absorbs, distributes, metabolizes and eliminates the compound.
This work is unglamorous, slow, and cannot be compressed. It is also where a program discovers cheaply that a molecule is not viable.
CMC — can you actually make it?
Chemistry, Manufacturing and Controls is the discipline most often underestimated by people new to the field, and the one that most often moves a filing date.
CMC has to answer: what is the synthetic route, is it reproducible, what are the impurities and are they acceptable, how is the finished product formulated, what analytical methods prove identity and purity, and how long is it stable. Every one of those answers must hold not just in a research laboratory but at commercial scale in a validated facility.
3. The IND — Permission to Begin
The Investigational New Drug application is what converts a laboratory compound into something legally administrable to humans in the United States. It packages the nonclinical safety data, the CMC information, and the proposed first clinical protocol.
The mechanic worth knowing: an IND is not approved. It is submitted, and if the agency does not object within 30 days, the sponsor may proceed. Silence is permission. If the agency has concerns it issues a clinical hold, and dosing cannot begin until the hold is resolved.
In this program the IND cleared its 30-day review in June 2023. Note how the suite treats it: Gate 2 is a submission gate and releases no funding tranche. The agency's review clock is a regulatory event, not a governance decision, and building a funding gate around it would hand the release schedule to an external timetable.
4. The Three Clinical Phases
Each phase answers a different question. Running them out of order, or asking one to answer another's question, is the most common conceptual error.
Phase 1 — safety and pharmacokinetics
Small, usually healthy volunteers, usually not looking for efficacy at all. Two designs run in sequence: single ascending dose, then multiple ascending dose. The questions are what the body does to the drug, what the drug does to the body at increasing exposures, and where tolerability starts to degrade.
In this program: 64 volunteers over 12 weeks.
Phase 2 — does it work, and at what dose
Patients with the actual condition, several dose arms, a control. This is the first honest test of the hypothesis and it is where most programs end.
The design choice that matters most is dose span. A narrow span is cheaper and answers the selection question. A wider span costs more and also tells you where the ceiling is. This program deliberately carried a wide span — 480 participants over 36 weeks — specifically so that if tolerability degraded at the top dose, it would degrade in Phase 2 where the finding is affordable rather than in Phase 3 where it is not.
Phase 3 — confirmation at scale
Large, long, and designed to support a label rather than to answer a scientific question. The endpoints are agreed with the agency in advance. The population matches the intended indication. The comparison is usually against placebo, sometimes against standard of care.
In this program: 2,480 participants across two pivotal trials of 68 weeks, plus a nested cardiovascular sub-study. That is $109,100,000, 50% of the entire program budget.
5. Talking to the Agency
FDA interactions are formal, scheduled, minuted, and far more consequential than their frequency suggests. Four matter across a development program.
| Meeting | When | What it settles |
|---|---|---|
| Pre-IND | Before the IND is filed | Whether the nonclinical package is sufficient and the first-in-human design is acceptable |
| End-of-Phase-1 | After Phase 1 reads out | Phase 2 design and dose selection |
| End-of-Phase-2 | After Phase 2 reads out | The pivotal design, the endpoints, and the safety expectations. The most consequential meeting in a development program. |
| Pre-NDA | Before submission | Content and format of the filing, integrated summaries, labeling strategy |
In this program that meeting on 19 May 2026 fixed the co-primary endpoints and produced the cardiovascular safety expectation that became CR-02 — a $7,200,000 scope addition and six months of schedule. Gate 4 was deliberately scheduled after it, so the $125,800,000 Phase 3 authorization was taken with the agency's position known rather than assumed.
6. Filing and Review
What an NDA is
A New Drug Application is the complete evidentiary case for a specific label. It is organized in modules covering administrative information, summaries, quality (CMC), nonclinical study reports, and clinical study reports. It typically runs to hundreds of thousands of pages.
Two filing routes matter:
- 505(b)(1) — a new molecular entity. The sponsor owns and submits every piece of the evidence. This program's route (Decision D-01).
- 505(b)(2) — relies partly on the agency's prior findings for a listed drug. Cheaper and faster where a suitable reference exists.
The review clock
Submission does not start the clock. The agency has 60 days to decide whether the application is complete enough to review — filing acceptance. From that point a standard review runs about 10 months to the PDUFA action date, the date by which the agency commits to respond. Priority review compresses this to roughly 6 months.
During review the agency issues information requests, which arrive with short deadlines and consume the sponsor team continuously. Labeling is negotiated in the final months.
Pre-approval inspection
Before approval, the agency inspects the manufacturing site. Observations are issued on Form 483. Unresolved significant observations delay approval regardless of how good the clinical data are.
7. Who Does What
A development program is a coalition of specialist functions, most of which do not report to the program manager.
| Function | Owns |
|---|---|
| Clinical Development | Protocol design, medical monitoring, interpretation |
| Clinical Operations | Trial execution, sites, monitoring, the CRO relationship |
| Biostatistics | Analysis plan, randomization, sample size, the read-out |
| Data Management | Database design, data cleaning, query resolution, lock |
| Nonclinical / Toxicology | Animal safety, IND-enabling package |
| CMC / Technical Operations | Making the drug, at scale, to specification |
| Quality Assurance | GxP compliance, audits, inspection readiness |
| Pharmacovigilance | Adverse event collection, expedited reporting, signal detection |
| Regulatory Affairs | Agency strategy, submissions, the relationship |
| Market Access | Payer evidence, pricing, reimbursement |
| Program Management | The seams between all of the above |
External partners
Most of the money leaves the building. A CRO runs the trials, a CMO manufactures, a central laboratory processes samples. In this program, internal salary is 17% of the budget and the other 83% is external.
8. Where Program Management Actually Adds Value
A sponsor program manager does not design the trial, write the protocol, run the statistics or make the drug. Every one of those belongs to a specialist function. So what is the job?
| Contribution | What it looks like |
|---|---|
| Owning the seams | Nobody else is accountable for the handoff between CMC readiness and the filing date, or between database lock and topline analysis. That is where programs lose time. |
| Sequencing decisions against information | Scheduling a gate after the agency meeting rather than before it. Knowing that a decision taken six weeks early is taken blind. |
| Making commitment staged rather than total | Tranche release, staged vendor work packages, and the discipline not to contract scope a future gate may decline to fund. |
| Surfacing weak positions in writing | A condition with a fixed verification method, an abstention with its reason recorded, a risk named before it becomes an issue. |
| Translating between functions | Clinical, CMC, regulatory and commercial all have valid and competing timelines. Someone has to hold all four at once. |
| Protecting the decision from the desire | Every program wants to proceed. The governance system exists so that wanting to is not sufficient. |
Under enrolment pressure the tempting moves are all in the fixed column: relax an exclusion, shorten the treatment period, drop an endpoint. Each would help the schedule and each would cost the filing. The moves genuinely available are more sites, faster activation, or a decision to spend more. Knowing which is which before the pressure arrives is most of the job.
9. Vocabulary
| Term | Meaning |
|---|---|
| IND | Investigational New Drug application — permission to dose humans |
| NDA / BLA | New Drug Application (small molecules) / Biologics License Application |
| 505(b)(1) / 505(b)(2) | Full application / application relying partly on prior agency findings |
| PDUFA date | The agency's committed action date on a filing |
| GLP / GCP / cGMP | Good Laboratory / Clinical / current Good Manufacturing Practice |
| GxP | Collective term for the above |
| CRO / CMO | Contract Research Organization / Contract Manufacturing Organization |
| CMC | Chemistry, Manufacturing and Controls |
| DMC / DSMB | Data Monitoring Committee — independent unblinded safety oversight |
| IRB / EC | Institutional Review Board / Ethics Committee — site-level human subject protection |
| SAE | Serious Adverse Event — carries expedited reporting obligations |
| Estimand | The precise quantity a trial is estimating, including how dropouts are treated |
| Screen failure | A consented participant who does not meet eligibility and is not randomized |
| Database lock | The point at which trial data are frozen for analysis |
| Topline | First unblinded summary of whether the primary endpoint was met |
| Form 483 | Written observations issued at the close of an FDA inspection |
| REMS | Risk Evaluation and Mitigation Strategy — required risk controls on a label |
| Gross-to-net | The gap between list price and what the manufacturer actually receives |
| PoS / LOA | Probability of Success / Likelihood of Approval |
10. How to Read the Rest of This Suite
With the lifecycle in hand, the artifacts fall into a natural reading order.
- Program Story — the narrative arc, start here.
- Product Definition — what the program is trying to prove, and what it conceded.
- Program Charter — what was authorized, and what was deliberately not.
- Development Committee Charter and Gate Decision Framework — who decides and against what.
- Phase 3 Protocol Summary — the clinical work, from a program manager's angle.
- Program Budget — where the money goes and how it is released.
- RAID Log, Conditions and Contingency — what is uncertain and what it cost.
- Post-Launch Review — what actually happened, against all of the above.
- Sources & Benchmarks — how to check the numbers.